

A vision for pharmaceutical and biomedical innovation

Unmet need (incentives) – Basic research

European Perspective 2020

Dr S. Van der Spiegel

Team Leader, Substance of Human Origin


DG SANCO, European Commission

European Healthcare Deciders Forum

17 February 2011

London

Substances of Human Origin








Many Innovations

- Composed transplants
- Stem cell therapies
- Borderline products
(« grow your own SoHO »)
- Artificial organs






=



Access

- Legal permission
- Organisational set-up
- Recognize value
- Funding decisions






Barriers to overcome

- Knowledge/Know-how
- Quality and Safety
- Time and Money
- Public expectations
- Ethical concerns



Future roles for health authorities

Challenges



- Define research needs, set agenda
- Fund studies/research
- Align safety and quality norms
- Public information and debates
- Recognize valuable innovation
- Reward/incentivize (P&R, funding)
- Right organisational set-up

Conclusions

- Innovation provides a large list of new treatment options
- Authorities need to...
 - Reflect on what are healthcare needs
 - Provide consequent access and market-incentives for companies
 - Clear the path for innovation
- This will require coordination between authorities...
 - In charge of healthcare and healthcare budgets, research and legislators/regulators
 - Across borders